Reference : Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-hos...
Scientific journals : Article
Human health sciences : Hematology
http://hdl.handle.net/2268/77204
Cotransplantation of mesenchymal stem cells might prevent death from graft-versus-host disease (GVHD) without abrogating graft-versus-tumor effects after HLA-mismatched allogeneic transplantation following nonmyeloablative conditioning.
English
Baron, Frédéric mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
Lechanteur, Chantal mailto [Centre Hospitalier Universitaire de Liège - CHU > > Thérapie cellulaire >]
Willems, Evelyne mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
Bruck, France [Université de Liège - ULg > > GIGA-R : Hématologie >]
Baudoux, Etienne mailto [Centre Hospitalier Universitaire de Liège - CHU > > Thérapie cellulaire >]
Seidel, Laurence [Centre Hospitalier Universitaire de Liège - CHU > > Non budgétaires >]
Vanbellinghen, Jean-François [Université de Liège - ULg > > Biologie Moléculaire - Unilab-Lg > > > >]
Hafraoui, Kaoutar mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
Lejeune, Marie-Christine [Centre Hospitalier Universitaire de Liège - CHU > > HOSPITALISATION - NEUROLOGIE (SN -1) >]
Gothot, André mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie biologique et immuno hématologie >]
Fillet, Georges mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
Beguin, Yves mailto [Centre Hospitalier Universitaire de Liège - CHU > > Hématologie clinique >]
2010
Biology of Blood & Marrow Transplantation
Carden Jennings Publishing
16
6
838-47
Yes (verified by ORBi)
International
1083-8791
1523-6536
Charlottesville
VA
[en] mesenchymal stem cells ; hematopoietic cell transplantation ; nonmyeloablative ; graft-versus-host disease ; HLA-mismatched ; graft-versus-tumor effects
[en] Recent studies have suggested that coinfusion of mesenchymal stem cells (MSCs) the day of hematopoietic cell transplantation (HCT) might promote engraftment and prevent graft-versus-host disease (GVHD) after myeloablative allogeneic HCT. This prompted us to investigate in a pilot study whether MSC infusion before HCT could allow nonmyeloablative (NMA) HCT (a transplant strategy based nearly exclusively on graft-versus-tumor effects for tumor eradication) from HLA-mismatched donors to be performed safely. Twenty patients with hematologic malignancies were given MSCs from third party unrelated donors 30-120 minutes before peripheral blood stem cells (PBSCs) from HLA-mismatched unrelated donors, after conditioning with 2 Gy total body irradiation (TBI) and fludarabine. The primary endpoint was safety, defined as a 100-day incidence of nonrelapse mortality (NRM) <35%. One patient had primary graft rejection, whereas the remaining 19 patients had sustained engraftment. The 100-day cumulative incidence of grade II-IV acute GVHD (aGVHD) was 35%, whereas 65% of the patients experienced moderate/severe chronic GVHD (cGVHD). One-year NRM (10%), relapse (30%), overall survival (OS) (80%) and progression-free survival (PFS) (60%), and 1-year incidence of death from GVHD or infection with GVHD (10%) were encouraging. These figures compare favorably with those observed in a historic group of 16 patients given HLA-mismatched PBSCs (but no MSCs) after NMA conditioning, which had a 1-year incidence of NRM of 37% (P = .02), a 1-year incidence of relapse of 25% (NS), a 1-year OS and PFS of 44% (P = .02), and 38% (P = .1), respectively, and a 1-year rate of death from GVHD or infection with GVHD of 31% (P = .04). In conclusion, our data suggest that HLA-mismatched NMA HCT with MSC coinfusion appeared to be safe.
http://hdl.handle.net/2268/77204
also: http://hdl.handle.net/2268/80213
10.1016/j.bbmt.2010.01.011
Copyright 2010 American Society for Blood and Marrow Transplantation. Published by Elsevier Inc. All rights reserved.

File(s) associated to this reference

Fulltext file(s):

FileCommentaryVersionSizeAccess
Restricted access
20101125092422080.pdfPublisher postprint1.11 MBRequest copy

Bookmark and Share SFX Query

All documents in ORBi are protected by a user license.